Drug Trial Radar · NCT05584709
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
34
Planned (sponsor's estimate)
Start
Mar 2023
Primary completion
Aug 2025
Study completion Oct 2025
Sponsor
- Lead sponsor
- Sorrento Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any advanced solid tumor. The patients that will be treated with STI-6129 in this trial are advanced solid tumor patients who have received prior lines of treatment.
Conditions
- Advanced Solid Tumor
Interventions
STI-6129Biological
Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events by type, frequency, severity, and causality (safety)Time frame: Baseline through study completion at up to approximately 24 months
- Incidence of serious adverse events by type, frequency, severity, and causality (safety)Time frame: Baseline through study completion at up to approximately 24 months
- Incidence of dose-limiting toxicities (safety)Time frame: Baseline through study completion at up to approximately 24 months
- Incidence of neurotoxicity (safety)Time frame: Baseline through study completion at up to approximately 24 months
- Incidence of laboratory abnormalities (safety)Time frame: Baseline through study completion at up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Medical Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.